#United States #Cranford #CTCL #LYMPHIR #Citius Oncology

Citius Oncology's Milestone: First International Order of LYMPHIR™ to Europe

Citius Oncology, Inc., renowned for its focus on oncology pharmacology, has recently shipped its first international order of LYMPHIR™ (denileukin diftitox-cxdl) to the European continent. This pivotal development symbolizes a significant leap toward broadening patient access to their groundbreaking therapy for Stage I–III relapsed or refractory cutaneous T-cell lymphoma (CTCL).

This final step marks Citius's commitment to enhancing patient care beyond the United States following the drug's initial U.S. launch in December 2025. The distribution of LYMPHIR will occur through a network of regional distribution partners, who will facilitate access for suitable patients in compliance with local regulations across various European nations through Named Patient Programs (NPPs).

According to Citius's CEO, Leonard Mazur, this successful shipment underscores their determination to make LYMPHIR available globally to patients who have limited options and are in need. With physicians being able to request LYMPHIR for eligible patients via established NPPs, this initiative promises a much-needed conduit for those awaiting treatment amidst a landscape where alternative therapies may be lacking.

In addition to expanding its reach, Citius Oncology is vigorously engaged in enhancing awareness and education regarding LYMPHIR amongst healthcare professionals within the U.S. Through consistent efforts in formulary access and payer coverage, the company is working to ensure that both academic and community oncology centers can effectively implement this innovative treatment.

LYMPHIR gained the green light from the U.S. Food and Drug Administration (FDA) in August 2024, specifically for adults suffering from CTCL who have undergone at least one prior systemic therapy. The commercial debut in the U.S. set off a chain reaction aiming to establish a robust market presence, with management projecting that the initial market exceeds $400 million.

Despite its promising potential, LYMPHIR currently lacks approval from the European Medicines Agency (EMA). Access through Named Patient Programs remains contingent upon regional laws and regulations, which signifies Citius's approach to maintaining rigorous compliance while extending therapy distribution internationally.

LYMPHIR’s innovative mechanism lies in its unique formulation—a recombinant fusion protein that effectively targets IL-2 receptors on cancer cells. This targeted immune therapy is specifically designed to eradicate tumors by halting protein synthesis within these malignant cells, showcasing a promising alternative for patients battling CTCL.

Citius Oncology has also made strides in securing their intellectual property, leveraging complex technology and existing collaborations to solidify its market positioning further. By continuing to emphasize education and patient access, Citius is poised to strengthen its footprint, ultimately providing hope to patients worldwide.

As distribution unfolds in Europe, Citius remains committed to prioritizing patient safety, actively monitoring treatment responses, and adapting its strategies to fulfill local healthcare needs. With LYMPHIR, the company beckons a new era in targeted cancer therapies, extending not just treatment options but also hope to patients who have experienced barriers to effective care.

The world awaits keenly as this new chapter unfolds for Citius Oncology, promising a relentless pursuit of innovation in oncology and a steadfast commitment to patient care across global landscapes.